Urovant Sciences, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States201-500 Employees
Urovant Sciences, Inc. operates in the biotechnology research sector with a focus on urology. Based in Irvine, California, the company develops therapies and pursues licensing opportunities intended to advance urologic patient care. It brought GEMTESA (vibegron) 75 mg tablets to the U.S. market in 2021 for the treatment of overactive bladder, addressing symptoms such as urgency, urgency incontinence, and urinary frequency, and it maintains ongoing research programs, including an investigational gene therapy candidate, URO-902. The company serves patients and healthcare providers dealing with urologic conditions and aims to be recognized as a leading specialty firm rooted in trust and patient care. Corporate activity includes licensing and asset transactions, such as the exclusive license for vibegron in the European Economic Area that was acquired by Pierre Fabre Group in 2022. Urovant operates as a subsidiary of Sumitovant Biopharma Ltd. and has explored URO-902 in a Phase IIa trial, which earned a Best in Category award for interim data in 2022.